Affibody’s psoriatic arthritis therapy shows long-term promise New 52-week data for izokibep in psoriatic arthritis show sustained efficacy and a favorable safety profile.

Affibody's izokibep shows strong long-term results in psoriatic arthritis. New 52-week data from a Phase IIb/III trial presented at the ACR conference in Chicago

#News #PsoriaticArthritis #Rheumatology #ClinicalTrials #IL17 #Izokibep #ACR2025 #MedicalResearch

Affibody’s psoriatic arthritis therapy shows long-term promise New 52-week data for izokibep in psoriatic arthritis show sustained efficacy and a favorable safety profile.

Affibody's izokibep shows strong long-term results in psoriatic arthritis. New 52-week data from a Phase IIb/III trial presented at the ACR conference in Chicago

#News #PsoriaticArthritis #Rheumatology #ClinicalTrials #IL17 #Izokibep #ACR2025 #MedicalResearch

Affibody’s izokibep shows phase III success after past setbacks Affibody argues that izokibep’s high-potency selectivity for IL-17A could confer an advantage over broader IL-17 blockade strategies. Image Credit: 愚木混株 Yumu/ Unsplash. Affibody has announced positive Phase III results in hidradenitis suppurativa (HS), a chronic skin condition marked by painful nodules, abscesses, and draining fistulas. The Swedish company will present 16-week data from a 258-patient global study at the European Academy of Dermatology & Venereology (EADV) Congress in Paris taking place from 17 to 20 September.

Affibody reports positive Phase III results for izokibep in hidradenitis suppurativa, offering new hope for patients after past trial setbacks. Results to be presented at #EADV2025 in Paris.

#News #Biotech #ClinicalTrials #HidradenitisSuppurativa #Dermatology #Izokibep #Affibody #EADV2025

Affibody’s izokibep shows phase III success after past setbacks Affibody argues that izokibep’s high-potency selectivity for IL-17A could confer an advantage over broader IL-17 blockade strategies. Image Credit: 愚木混株 Yumu/ Unsplash. Affibody has announced positive Phase III results in hidradenitis suppurativa (HS), a chronic skin condition marked by painful nodules, abscesses, and draining fistulas. The Swedish company will present 16-week data from a 258-patient global study at the European Academy of Dermatology & Venereology (EADV) Congress in Paris taking place from 17 to 20 September.

Affibody reports positive Phase III results for izokibep in hidradenitis suppurativa, offering new hope for patients after past trial setbacks. Results to be presented at #EADV2025 in Paris.

#News #Biotech #ClinicalTrials #HidradenitisSuppurativa #Dermatology #Izokibep #Affibody #EADV2025

Izokibep produces multiple positive effects in phase 2 psoriatic arthritis study Phase 2 data show that the small protein therapeutic izokibep significantly reduces disease activity in people with active psoriatic arthritis versus placebo.

#MedNews - Phase 2 data show that the small protein therapeutic #izokibep significantly reduces disease activity in people with active psoriatic #arthritis versus placebo.

Read the full story now 👉 buff.ly/PTs3Gew

#RheumSky #Psoriasis

Very high placebo response, as with other trials, for #Izokibep trials for #hidradenitis. Response rate looks similar to other IL-17s despite novel MOA

#EADVCongress #EADV2024